

**NANOBIOTIX TO PARTICIPATE IN MULTIPLE INVESTOR CONFERENCES
IN FEBRUARY AND MARCH 2025**

Paris, France; Cambridge, Massachusetts (USA); January 29, 2025 - [NANOBIOTIX](#) (Euronext: NANO — NASDAQ: NBTX – the “**Company**”), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conferences:

Guggenheim SMID Cap Biotech Conference

Date: Thursday, February 6, 2025

Time: 1pm ET / 7pm CET

Location: New York, NY

Presenter: Bart van Rhijn, Chief Financial & Business Officer of Nanobiotix

Webcast link: [Click here](#)**Leerink Global Healthcare Conference**

Date: Wednesday, March 12, 2025

Time: 10:40pm ET / 4:40pm CET

Location: Miami, FL

Presenters: Laurent Levy, Chief Executive Officer of Nanobiotix and Bart van Rhijn, Chief Financial & Business Officer of Nanobiotix

Webcast link: [Click here](#)

The fireside chats will be webcast live from the [events page](#) of the Investors section of the Company's website. Replay of the webcast will be available following the event.

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company's philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.

Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on [LinkedIn](#) and [Twitter](#).

Contacts

Nanobiotix

Communications Department*Brandon Owens**VP, Communications*

+1 (617) 852-4835

contact@nanobiotix.com**Investor Relations Department***Craig West**SVP, Investor Relations*

+1 (617) 583-0211

investors@nanobiotix.com

Media Relations

France – **HARDY**
Caroline Hardy
+33 06 70 33 49 50
carolinehardy@outlook.fr

Global – **LifeSci Advisors**
Kevin Gardner
+1 (617) 283-2856
kgardner@lifesciadvisors.com

